{
  "stages": {
    "0": {
      "primary_treatments": ["Breast-conserving surgery", "Radiation"],
      "systemic": ["Endocrine therapy if ER/PR positive"],
      "alternatives": ["Mastectomy without radiation", "Clinical Trial"],
      "notes": "DCIS management focuses on local control"
    },
    "I": {
      "primary_treatments": ["TH (Paclitaxel + Trastuzumab) if HER2+", "Endocrine therapy if ER/PR+"],
      "targeted": ["Trastuzumab if HER2+"],
      "immunotherapy": [],
      "brca": ["Consider Olaparib in high-risk BRCA+"],
      "alternatives": ["AC-T (Adriamycin/Cyclophosphamide followed by Taxol)", "Clinical Trial"],
      "follow_up": ["Exam every 6-12m for 5y", "Annual mammogram"]
    },
    "II": {
      "primary_treatments": ["TCHP (Docetaxel + Carboplatin + Trastuzumab + Pertuzumab)"],
      "targeted": ["Trastuzumab 1y", "Pertuzumab optional"],
      "residual": ["Switch to T-DM1 if residual disease"],
      "brca": ["Olaparib 1y if BRCA+ high-risk"],
      "alternatives": ["AC-T with HER2 blockade", "Clinical Trial"],
      "follow_up": ["Exam q 3-6m for 5y", "Cardiac monitoring", "Annual mammogram"]
    },
    "III": {
      "primary_treatments": ["Neoadjuvant TCHP"],
      "surgery": ["Mastectomy or BCS + ALND"],
      "radiation": ["PMRT to chest wall & nodes"],
      "residual": ["T-DM1"],
      "brca": ["Olaparib"],
      "alternatives": ["Dose-dense AC-T", "Clinical Trial"],
      "follow_up": ["Exam q3-6m", "Cardiac monitoring"]
    },
    "IV": {
      "primary_treatments": ["HER2-targeted systemic therapy"],
      "targeted": ["Trastuzumab", "Pertuzumab", "T-DXd", "T-DM1"],
      "immunotherapy": ["Pembrolizumab if PD-L1+ TNBC"],
      "endocrine": ["AI + CDK4/6 inhibitor if ER+"],
      "alternatives": ["Tucatinib-based regimens", "Clinical Trial Participation"],
      "follow_up": ["Q2-3m imaging"]
    }
  }
}
